Canopy Growth Corporation, Smiths Falls, Canada.
Santé Cannabis, Westmount, Canada.
Cannabis Cannabinoid Res. 2021 Dec;6(6):564-572. doi: 10.1089/can.2020.0140. Epub 2021 May 10.
Despite increasing demand for data, little is known about the authorization patterns, safety, and effectiveness of medical cannabis products. We conducted a 2 year observational study of adult patients who were legally authorized a medical cannabis product from a single licensed producer; we captured and analyzed authorized cannabis use patterns by cannabinoid profile (tetrahydrocannabinol [THC]-dominant; cannabidiol [CBD]-dominant; and balanced (THC:CBD) and clinical outcomes using standardized outcome measures every 3 months for 12 months at a network of medical cannabis clinics in Quebec, Canada. We recruited 585 patients (average age 56.5 years), of whom 61% identified as female and 85% reported pain as their primary complaint. Over 12 months, there was a significant increase in the number of products authorized (=2.59, =0.01). The proportion of authorizations for a THC-dominant or CBD-dominant product increased relative to the proportion of authorizations for a balanced (THC:CBD) product (all <0.01). Symptom improvement over time was observed for pain, tiredness, drowsiness, anxiety, and well-being. Patients authorized THC-dominant products exhibited less symptom improvement for anxiety and well-being relative to those authorized CBD-dominant or balanced (THC:CBD) products. Medical cannabis was well tolerated across all product profiles. These real-world data reveal changes in medical cannabis authorization patterns and suggest that symptom improvement may vary by cannabinoid profile over 12 months of follow-up.
尽管对数据的需求不断增加，但人们对医用大麻产品的授权模式、安全性和有效性知之甚少。我们对来自单一许可生产商的合法授权医用大麻产品的成年患者进行了为期 2 年的观察性研究；我们通过大麻素谱（四氢大麻酚 [THC]-主导；大麻二酚 [CBD]-主导；平衡（THC:CBD））捕获和分析了授权大麻使用模式，并使用标准化结局测量方法在加拿大魁北克的一个医用大麻诊所网络中每 3 个月对 12 个月的临床结局进行了分析。我们招募了 585 名患者（平均年龄 56.5 岁），其中 61%为女性，85%报告疼痛是他们的主要主诉。在 12 个月内，授权的产品数量显著增加（=2.59，=0.01）。与授权平衡（THC:CBD）产品相比，THC 主导或 CBD 主导产品的授权比例增加（均<0.01）。随着时间的推移，疼痛、疲劳、嗜睡、焦虑和幸福感等症状都有所改善。与授权 THC 主导或平衡（THC:CBD）产品的患者相比，授权 THC 主导产品的患者在焦虑和幸福感方面的症状改善较少。所有产品类型的医用大麻均具有良好的耐受性。这些真实世界的数据揭示了医用大麻授权模式的变化，并表明在 12 个月的随访中，症状改善可能因大麻素谱而异。
